BDRX - Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential | Benzinga
Biodexa Pharmaceuticals (NASDAQ:BDRX), developing MTX110 for Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults, says early trials of MTX110 in both brain cancers show promise in extending survival rates beyond those reported in previously published studies.
The main chemotherapy agent of MTX110, panobinostat, was initially used to treat multiple myeloma and received FDA approval in 2015.
The company is reworking the chemotherapy agent by changing its delivery method and leveraging Convection Enhanced Delivery (CED) technology.
Researchers discovered that the original formulation of panobinostat could block enzymes involved in cancer cell growth, exhibiting high potency against brain stem ...